Drug Delivery Technologies

PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration
Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration
Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
IntelGenx's Q4 And Full-Year 2022 Financials, 'On The Cusp' Of Rapid Growth?

Drug Delivery Technologies Recent News

A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral,
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Specialty ketamine company PharmaTher Holdings Ltd.
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect
New Sublingual Psychedelic Drug Candidate Created For Depression And Anxiety In Alzheimer's
Psychedelics R&D biotech Biomind Labs Inc.
Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial
Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD).
Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track
Drug delivery company IntelGenx Corp.
New At-Home Multiple Drugs Formulation Delivery Technology Scores US Patent
SEVALENT, Bexson Biomedical’s disrupting offer ready for the small molecule injectable market, received patent allowance by the USPTO for “Complexing Agent Salt Formulations of Pharmaceutical Compounds.” 
Psychedelics Companies Seek Innovative Methods To Deliver Assisted Therapies, This One Stands Out
As competence grows, biopharmaceuticals are searching for ways to present their specific psychedelic substance-assisted therapies in a way that might differentiate them from their competitors while maintaining safety and efficiency standards.
New Report Top 10 Drug Delivery Technologies (2010 - 2015) Published by MarketsandMarkets